General anesthesia leads to better functional outcomes than conscious sedation in stroke patients with large vessel occlusion ...

CStone Pharmaceuticals ( OTCPK:CSPHF) Discusses CS2009 Data Interpretation and Future Clinical Development Strategy October 20, 2025 9:00 AM EDT ...

Astria Therapeutics, Inc. acquired by BioCryst for $13 per share, with the deal set to finalize in 1Q26. Click here to read ...

Pfizer Inc. (NYSE: PFE) today announced updated follow-up results from the single-arm Phase 2 PHAROS trial evaluating BRAFTOVI® (encorafenib ...

This study aimed to evaluate diurnal and seasonal trends in aerodynamic conductance over a grassland surface. A simple ...

ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and ...

Positive results from the DESTINY-Breast05 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) demonstrated a highly statistically significant and clinically meaningful improvement in ...

The five-year invasive disease-free survival (iDFS) rates were 85.5% in the Kisqali plus ET arm versus 81.0% in the ET alone arm, representing a clinically meaningful 4.5% improvement 1. These ...

Emerging evidence indicates that sustainable lifestyle changes—such as increasing physical activity, adopting healthy dietary ...

Explore trusted casinos offering a brand new online casinos USA no deposit bonus and USA no deposit bonus deals in 2025.

Objectives To describe injury epidemiology in British basketball, assess sex-based differences and injury risk ...